These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 32209836)

  • 41. Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.
    Shishko I; Almeida K; Silvia RJ; Tataronis GR
    Pharmacogenomics; 2015; 16(9):949-58. PubMed ID: 26100610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients.
    Jablonski MR; Lorenz R; Li J; Dechairo BM
    J Geriatr Psychiatry Neurol; 2020 Nov; 33(6):324-332. PubMed ID: 31842673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.
    Haga SB; Moaddeb J; Mills R; Voora D
    Pharmacogenomics; 2017 Mar; 18(4):327-335. PubMed ID: 28244804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Companies Tout Psychiatric Pharmacogenomic Testing, But Is It Ready for a Store Near You?
    Abbasi J
    JAMA; 2018 Oct; 320(16):1627-1629. PubMed ID: 30285065
    [No Abstract]   [Full Text] [Related]  

  • 45. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
    Solomon HV; Cates KW; Li KJ
    Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
    BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
    Hachad H; Ramsey LB; Scott SA
    Clin Pharmacol Ther; 2019 Aug; 106(2):298-301. PubMed ID: 31162629
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacogenetics in psychiatric care, a call for uptake of available applications.
    Lunenburg CATC; Gasse C
    Psychiatry Res; 2020 Oct; 292():113336. PubMed ID: 32739644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contribution of Pharmacogenetic Testing to Modeled Medication Change Recommendations in a Long-Term Care Population with Polypharmacy.
    Sugarman EA; Cullors A; Centeno J; Taylor D
    Drugs Aging; 2016 Dec; 33(12):929-936. PubMed ID: 27826798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. "Black box" pharmacogenetic decision-support tools in psychiatry.
    Bousman CA; Eyre HA
    Braz J Psychiatry; 2020 Apr; 42(2):113-115. PubMed ID: 31994639
    [No Abstract]   [Full Text] [Related]  

  • 51. Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?-Results from the ADRED Study.
    Just KS; Dormann H; Schurig M; Böhme M; Fracowiak J; Steffens M; Scholl C; Seufferlein T; Gräff I; Schwab M; Stingl JC
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32527038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Innovative Canadian Pharmacogenomic Screening Initiative in Community Pharmacy (ICANPIC) study.
    Papastergiou J; Tolios P; Li W; Li J
    J Am Pharm Assoc (2003); 2017; 57(5):624-629. PubMed ID: 28689706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.
    Lee YM; McKillip RP; Borden BA; Klammer CE; Ratain MJ; O'Donnell PH
    Pharmacogenet Genomics; 2017 May; 27(5):179-189. PubMed ID: 28267054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
    Bergmeijer TO; Vos GJ; Claassens DM; Janssen PW; Harms R; der Heide RV; Asselbergs FW; Ten Berg JM; Deneer VH
    Pharmacogenomics; 2018 May; 19(7):621-628. PubMed ID: 29701129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.
    Pratt VM; Cavallari LH; Del Tredici AL; Hachad H; Ji Y; Moyer AM; Scott SA; Whirl-Carrillo M; Weck KE
    J Mol Diagn; 2019 Sep; 21(5):746-755. PubMed ID: 31075510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age- vs. Genotype-Related Differences.
    Dücker CM; Brockmöller J
    Clin Pharmacol Ther; 2019 Mar; 105(3):625-640. PubMed ID: 29498032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicians' perceptions of pharmacogenomics use in psychiatry.
    Chan CY; Chua BY; Subramaniam M; Suen EL; Lee J
    Pharmacogenomics; 2017 Apr; 18(6):531-538. PubMed ID: 28290747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
    Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
    Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient experiences with pharmacogenetic testing in a primary care setting.
    Haga SB; Mills R; Moaddeb J; Allen Lapointe N; Cho A; Ginsburg GS
    Pharmacogenomics; 2016 Oct; 17(15):1629-1636. PubMed ID: 27648637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. History repeats itself: the family medication history and pharmacogenomics.
    Smith TR; Kearney E; Hulick PJ; Kisor DF
    Pharmacogenomics; 2016 May; 17(7):669-78. PubMed ID: 27143300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.